Schwab Charles Investment Management Inc. lessened its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 26.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,061 shares of the company’s stock after selling 32,900 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.37% of USANA Health Sciences worth $5,902,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. FMR LLC boosted its stake in USANA Health Sciences by 7.1% during the 1st quarter. FMR LLC now owns 1,538,110 shares of the company’s stock worth $88,595,000 after purchasing an additional 102,086 shares during the last quarter. Vanguard Group Inc. boosted its stake in USANA Health Sciences by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 954,590 shares of the company’s stock worth $54,984,000 after purchasing an additional 36,655 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in USANA Health Sciences by 1.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 695,170 shares of the company’s stock worth $40,042,000 after purchasing an additional 9,293 shares during the last quarter. Teachers Advisors LLC boosted its stake in USANA Health Sciences by 2.5% during the 1st quarter. Teachers Advisors LLC now owns 223,128 shares of the company’s stock worth $12,852,000 after purchasing an additional 5,451 shares during the last quarter. Finally, Morgan Stanley boosted its stake in USANA Health Sciences by 1.5% during the 1st quarter. Morgan Stanley now owns 202,869 shares of the company’s stock worth $11,685,000 after purchasing an additional 3,003 shares during the last quarter. 44.85% of the stock is currently owned by institutional investors.
In related news, Director Myron W. Wentz sold 40,000 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $57.54, for a total transaction of $2,301,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jim Brown sold 16,574 shares of the stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $58.84, for a total value of $975,214.16. Following the sale, the chief operating officer now directly owns 2,175 shares in the company, valued at approximately $127,977. The disclosure for this sale can be found here. Insiders sold 386,340 shares of company stock worth $22,270,913 in the last three months. 53.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Schwab Charles Investment Management Inc. Sells 32,900 Shares of USANA Health Sciences, Inc. (USNA)” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2017/10/12/schwab-charles-investment-management-inc-sells-32900-shares-of-usana-health-sciences-inc-usna.html.
USNA has been the topic of several recent research reports. BidaskClub cut shares of USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, September 22nd. Pivotal Research lowered their target price on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, July 26th.
Shares of USANA Health Sciences, Inc. (NYSE USNA) opened at 60.60 on Thursday. The firm has a market cap of $1.48 billion, a PE ratio of 15.74 and a beta of 1.09. USANA Health Sciences, Inc. has a 52 week low of $52.55 and a 52 week high of $75.00. The firm’s 50-day moving average is $58.15 and its 200 day moving average is $60.18.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.08). The firm had revenue of $257.10 million during the quarter, compared to analyst estimates of $273.61 million. USANA Health Sciences had a net margin of 9.47% and a return on equity of 28.93%. The firm’s revenue for the quarter was down .5% on a year-over-year basis. During the same period last year, the company posted $2.07 EPS. Equities research analysts forecast that USANA Health Sciences, Inc. will post $3.79 EPS for the current year.
USANA Health Sciences announced that its board has approved a share repurchase plan on Tuesday, July 25th that authorizes the company to buyback $64.60 million in outstanding shares. This buyback authorization authorizes the company to buy up to 46% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
USANA Health Sciences Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
What are top analysts saying about USANA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for USANA Health Sciences Inc. and related companies.